SG11202107606VA - Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy - Google Patents
Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapyInfo
- Publication number
- SG11202107606VA SG11202107606VA SG11202107606VA SG11202107606VA SG11202107606VA SG 11202107606V A SG11202107606V A SG 11202107606VA SG 11202107606V A SG11202107606V A SG 11202107606VA SG 11202107606V A SG11202107606V A SG 11202107606VA SG 11202107606V A SG11202107606V A SG 11202107606VA
- Authority
- SG
- Singapore
- Prior art keywords
- polypeptides
- therapy
- interleukin
- mutated
- mutated interleukin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2334—Interleukin-34 (IL-34)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
- C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19305046 | 2019-01-15 | ||
| PCT/EP2020/050920 WO2020148338A1 (en) | 2019-01-15 | 2020-01-15 | Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202107606VA true SG11202107606VA (en) | 2021-08-30 |
Family
ID=65228484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202107606VA SG11202107606VA (en) | 2019-01-15 | 2020-01-15 | Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy |
Country Status (13)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023246908A1 (zh) * | 2022-06-21 | 2023-12-28 | 四川大学华西医院 | 靶向csf1r的嵌合抗原受体免疫细胞制备及其应用 |
| CN115819614B (zh) * | 2022-06-21 | 2024-02-23 | 四川大学华西医院 | 一种基于il34的嵌合抗原受体免疫细胞制备及其应用 |
| CN115252764A (zh) * | 2022-08-09 | 2022-11-01 | 南方医科大学 | 一种白介素在制备治疗急性髓系白血病的药物中的应用 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR520E (fr) | 1901-11-13 | 1903-01-26 | Bermont Victor Etienne | Procédé industriel d'extraction directe du zinc contenu dans les minerais oxydés, et plus spécialement dans la smithsonite (znco3) et la calamine (h2zn2sio5) |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| CA2357538A1 (en) | 1989-03-21 | 1990-10-04 | Wisconsin Alumni Research Foundation | Expression of exogenous polynucleotide sequences in a vertebrate |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| WO1994004678A1 (en) | 1992-08-21 | 1994-03-03 | Casterman Cecile | Immunoglobulins devoid of light chains |
| DE69434860T2 (de) | 1993-02-22 | 2007-03-15 | The Rockefeller University | Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion |
| FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
| EP0753069A1 (en) | 1994-04-15 | 1997-01-15 | Targeted Genetics Corporation | Gene delivery fusion proteins |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| ID29991A (id) | 1998-12-23 | 2001-10-25 | Pfizer Inc Cs | Antibodi monoklonal manusia pada ctla-4 |
| KR100996759B1 (ko) | 1999-08-24 | 2010-11-25 | 메다렉스, 인코포레이티드 | 인간 씨티엘에이-4 항체 및 그의 용도 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| WO2001054732A1 (en) | 2000-01-27 | 2001-08-02 | Genetics Institute, Llc. | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| HRP20030071B1 (hr) | 2000-07-03 | 2014-01-03 | Bristol-Myers Squibb Company | Postupci za lijeäśenje reumatskih bolesti uporabom topljivih ctla4 mutantnih molekula |
| AR036852A1 (es) | 2001-10-19 | 2004-10-06 | Isotechnika Inc | Preconcentrado de una microemulsion de analogos de ciclosporina, su metodo de preparacion y metodos para producir inmunosupresion |
| CN1729203B (zh) | 2002-10-17 | 2014-02-19 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| MXPA05006828A (es) | 2002-12-23 | 2005-09-08 | Wyeth Corp | Anticuerpos contra pd-1, y sus usos. |
| EP2287310B1 (en) * | 2004-07-22 | 2015-05-06 | Five Prime Therapeutics, Inc. | Compositions and methods using MGD-CSF in disease treatment |
| MX2007013978A (es) | 2005-05-09 | 2008-02-22 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos a muerte programada 1 (pd-1) y metodos para tratamiento de cancer utilizando anticuerpos anti-pd-1 solos o en combinacion con otros inmunoterapeuticos. |
| ES2546333T3 (es) | 2005-07-01 | 2015-09-22 | E. R. Squibb & Sons, L.L.C. | Anticuerpos monoclonales humanos para ligandos 1 (PD-L1) de muerte programada |
| SG153832A1 (en) | 2005-12-20 | 2009-07-29 | Bristol Myers Squibb Co | Stable protein formulations |
| AU2009213738B2 (en) | 2008-02-11 | 2015-01-22 | Curetech Ltd. | Monoclonal antibodies for tumor treatment |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| PL2350129T3 (pl) | 2008-08-25 | 2015-12-31 | Amplimmune Inc | Kompozycje antagonistów PD-1 i sposoby stosowania |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| TW202442680A (zh) | 2008-12-09 | 2024-11-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| WO2010117057A1 (ja) | 2009-04-10 | 2010-10-14 | 協和発酵キリン株式会社 | 抗tim-3抗体を用いた血液腫瘍治療法 |
| US8289808B2 (en) | 2009-04-16 | 2012-10-16 | Chevron U.S.A., Inc. | System and method to estimate compressional to shear velocity (VP/VS) ratio in a region remote from a borehole |
| HRP20171653T1 (hr) | 2009-11-24 | 2017-12-15 | Medimmune Limited | Vezna sredstva koja služe ciljano protiv b7-h1 |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| ES2682078T3 (es) | 2010-06-11 | 2018-09-18 | Kyowa Hakko Kirin Co., Ltd. | Anticuerpo anti-TIM-3 |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| WO2013079174A1 (en) | 2011-11-28 | 2013-06-06 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
| EA031470B1 (ru) | 2013-03-15 | 2019-01-31 | Бристол-Майерс Сквибб Компани | Ингибиторы ido |
| RS57508B1 (sr) | 2013-09-06 | 2018-10-31 | Aurigene Discovery Tech Ltd | 1,2,4-derivati oksadiazola kao imunomodulatori |
| EP3385257A1 (en) | 2013-09-06 | 2018-10-10 | Aurigene Discovery Technologies Limited | 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators |
| ES2710444T3 (es) * | 2014-07-17 | 2019-04-25 | Inst Nat Sante Rech Med | Un polipéptido de interleucina 34 aislado para uso en la prevención del rechazo de trasplante y el tratamiento de enfermedades autoinmunitarias |
| JP2018516933A (ja) * | 2015-06-02 | 2018-06-28 | ジェネンテック， インコーポレイテッド | 抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法 |
| CN106084030B (zh) | 2016-04-25 | 2019-11-08 | 北京大学 | 一种提高白细胞介素il-34热稳定性的方法 |
-
2020
- 2020-01-15 KR KR1020217024902A patent/KR20210121077A/ko active Pending
- 2020-01-15 ES ES20700307T patent/ES3011707T3/es active Active
- 2020-01-15 IL IL284868A patent/IL284868B2/en unknown
- 2020-01-15 EP EP20700307.0A patent/EP3911670B1/en active Active
- 2020-01-15 WO PCT/EP2020/050920 patent/WO2020148338A1/en not_active Ceased
- 2020-01-15 BR BR112021013944A patent/BR112021013944A8/pt unknown
- 2020-01-15 SG SG11202107606VA patent/SG11202107606VA/en unknown
- 2020-01-15 US US17/422,556 patent/US20220098264A1/en active Pending
- 2020-01-15 CA CA3126741A patent/CA3126741A1/en active Pending
- 2020-01-15 JP JP2021540589A patent/JP7645185B2/ja active Active
- 2020-01-15 CN CN202080017907.2A patent/CN113508129B/zh active Active
- 2020-01-15 AU AU2020208909A patent/AU2020208909B2/en active Active
- 2020-01-15 MX MX2021008525A patent/MX2021008525A/es unknown
-
2024
- 2024-09-20 JP JP2024163874A patent/JP2025000723A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021013944A8 (pt) | 2023-02-07 |
| MX2021008525A (es) | 2021-11-12 |
| AU2020208909A1 (en) | 2021-07-29 |
| IL284868B2 (en) | 2025-09-01 |
| JP2025000723A (ja) | 2025-01-07 |
| JP7645185B2 (ja) | 2025-03-13 |
| BR112021013944A2 (enrdf_load_stackoverflow) | 2021-11-21 |
| KR20210121077A (ko) | 2021-10-07 |
| IL284868B1 (en) | 2025-05-01 |
| US20220098264A1 (en) | 2022-03-31 |
| IL284868A (en) | 2021-08-31 |
| EP3911670C0 (en) | 2024-12-25 |
| EP3911670A1 (en) | 2021-11-24 |
| CN113508129A (zh) | 2021-10-15 |
| CA3126741A1 (en) | 2020-07-23 |
| ES3011707T3 (en) | 2025-04-08 |
| AU2020208909B2 (en) | 2025-02-20 |
| JP2022517029A (ja) | 2022-03-03 |
| WO2020148338A1 (en) | 2020-07-23 |
| EP3911670B1 (en) | 2024-12-25 |
| CN113508129B (zh) | 2025-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287781A (en) | Clec-12a binding polypeptides and uses thereof | |
| IL265489B (en) | Recombinant binding proteins and their uses | |
| IL283241A (en) | High potency transgenic tm-phytase polypeptides and their fragments | |
| IL280808A (en) | OX40-binding polypeptides and their uses | |
| IL287782A (en) | 33cd-binding polypeptides and their uses | |
| GB2603645B (en) | Polypeptides having anti-senescent effects and uses thereof | |
| SG11202107606VA (en) | Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy | |
| SG10201912408WA (en) | Chimeric polypeptides and methods of altering their localisation in the cell membrane | |
| EP3816186A4 (en) | PD-L1 BINDING POLYPEPTIDE AND USE | |
| IL261397A (en) | Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophy | |
| EP3813861A4 (en) | HEPARIN-ASSOCIATED POLYPEPTIDES AND THEIR USES | |
| GB2600592B (en) | Polypeptide and use thereof | |
| GB201819200D0 (en) | Polypeptide and uses thereof | |
| GB201819850D0 (en) | Polypeptide and its use in affinity purification | |
| GB202201003D0 (en) | Fusion polypeptide and use thereof | |
| GB202109082D0 (en) | Polypeptides and uses thereof | |
| GB202201004D0 (en) | Reconbinant fusion polypeptide and use thereof | |
| EP4081235A4 (en) | HEPARIN-ASSOCIATED POLYPEPTIDES AND THEIR USE | |
| EP3256578B8 (en) | Polypeptides for engineering integrase chimeric proteins and their use in gene therapy | |
| HK40062285A (en) | Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy | |
| IL304183A (en) | Actinohibin variant polypeptides and related methods | |
| GB2582571B (en) | Peptides and use thereof | |
| EP3425054C0 (en) | MUTANT CYTOCHROME PROTEIN AND USE THEREOF | |
| IL278009A (en) | History of 6,2-diamino-4,3-dihydropyrimidin-4-one and its use in treatment | |
| IL275241A (en) | - Engineered glycosylation in recombinant polypeptides and uses thereof |